Monday, September 18, 2006


Terms defined:

MHRA: Medicines and Healthcare products Regulatory Agency, Britain's version
of the FDA.

Strattera: failed antidepressant repackaged as a non-stimulant treatment for
ADHD. Strattera is a NRI, for Norepinephrine reuptake inhibitor other drugs
that affect the same area of the brain are SNRI drugs that include Effexor
(Andrea Yates), Cymbalta (Traci Johnson hung herself in Lilly's research lab
on this drug. She was a healthy test subject) and Serzone (FDA 2001 warning
of severe liver damage, Public Citizen sued FDA for not removing the drug)
along with serotonin.
------------------------------------------------------------------------
-----------------
Strattera - 10,988 adverse "psychiatric reactions" reported in
less than three years

In less than three years 10,988 adverse "psychiatric reactions"
have been reported to Eli Lilly for the ADHD drug Strattera.
This is revealed in a document treated as a "state secret" by the British
and Swedish medical agencies.

/24-7PressRelease/ - HAGERSTEN, SWEDEN, August 01,
2006
- The document, Psychiatric Adverse Events including Cumulative review of
spontaneous reports of suicidal and self-injurious behaviour, is an
attachment to an unpublished report about Strattera from the British
Medicines and Healthcare products Regulatory Agency (MHRA), January 2006.
The attachment, mentioning the 10,988 "psychiatric reactions", also gives a
good insight into how psychiatric drugs and drug cocktails are killing
children and adults, and how psychiatric diagnoses are used to hide the
harmful effects of drugs.

A court in Sweden has recently ordered the document to be
made public. This was done after the Swedish Medical Products Agency
(MPA) and the British MHRA in their response to FOIA requests had treated
this document as if it was a "state secret". In its arguments to the court
the Swedish MPA even said that issuance of it would hurt the relations
between Sweden and UK. Neither the British National Institute for Health and
Clinical Excellence (NICE), responsible for "guidance on the appropriate
treatment", being in possession of the document, was willing to reveal the
data in it. NICE said in an answer to a FOIA-request that the document was
"received in confidence and disclosure of that information would amount to
an actionable breach of confidence".

These agencies, responsible for protecting the public
from harmful drugs and for "appropriate treatment", consider a document
reviewing the "suicidal and self-injurious behaviour" caused by a
psychiatric drug in the category of state secrets, and that it would be "an
actionable breach of confidence" to let the public know about these data.

But a court in Sweden has made the document public.
The document consists mainly of Eli Lilly's review of the 431 cases of
suicidal and self-injurious behaviour reported for Strattera from November
2002 up to October 2005. 130 of these reports were submitted in one month
(October 2005), after the warnings were issued in September that Strattera
increased the risk for suicidality.

Lilly's review is an excellent example of how to explain
away suicides, suicide attempts and suicide ideation caused by psychiatric
drugs - and of how the assessing medical agency then buys these
explanations.

It can be seen in the review that children and
adolescents in many cases are getting psychiatric drug cocktails - Strattera
together with antidepressant SSRI drugs (as Zoloft and Prozac) and
antipsychotic drugs (as Risperidone and Zyprexa). The reason for the adding
of more drugs to the first one, is that one psychiatric drug's harmful
effect - according to the psychiatric ideology - is seen as yet another
"psychiatric disorder", to be treated with yet another mind altering
(poisonous) drug. And so on.

The alleged psychiatric brain disorder ADHD (without any
objective abnormality) is NOT associated with suicidal thoughts in its list
of "symptoms". However as the reports of suicidal behaviour from "treatment"
with Strattera kept coming in, Eli Lilly had to connect depression and
suicidal behaviour with ADHD, to exonerate the drug and blame it on the
children's "underlying condition". For this purpose Eli Lilly claimed in its
submission to the FDA in September 2005:
"Depression is present in up to 40% ...of ADHD adolescents and children."

It is very convenient for drug companies that
psychiatrists are adding more poisonous drugs to the first one when its
harmful effects are showing up. No single drug can then be blamed for the
death of children. It is even more convenient to blame the harmful effects
of a drug on a (presumed) "underlying condition". This is what Eli Lilly and
the psychiatric experts at the MHRA are doing when they in cases of suicidal
behaviour in connection with Strattera find "confounding factors"
present. No matter how obvious the case of poisoning the conclusions from
the medical agency become (at best): "the possibility that atomoxetine
[Strattera] may have exacerbated the individuals underlying condition in
these cases cannot be excluded."

In its report about Strattera (January 2006) the MHRA
talks about "the large number of psychiatric reactions". It says the agency
in September 2005, due to this large number of harmful effects, had
requested Eli Lilly "to perform a cumulative review of all psychiatric
disorders reported for atomoxetine [Strattera]".

In the attachment, containing the review by Eli Lilly of
suicidal behaviour, no review of "the large number of psychiatric reactions"
can be found. What can be found is the number of reported reactions (up to
September 2005): 10,988 adverse "psychiatric reactions"

described in 6,751 reports. Example of reactions: The two categories
aggression and anger are reported in 1117 cases, abnormal behaviour in
989 cases, and homicidal ideation in 19 cases.

The MHRA has still not let the public know any details
about this "large number of psychiatric reactions". Neither has the agency
let the public know the updated figures for suicidal behaviour in connection
with Strattera.

Janne Larsson
writer from Sweden - investigating psychiatry

No comments: